Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 ...

Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were ...

REZLIDHIA more than doubled both bottles shipped ... dependent lower-risk MDS and orphan drug designation for MDS by the FDA. Furthermore, as part of Rigel-sponsored development programs and ...

Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the company fares in Q4, we recommend investors to add the stock to their ...

Beginning Friday night, FDA employees overseeing medical devices, food ingredients and other key areas received calls and emails notifying them that their recent terminations had been “rescinded ...